Background: Atherosclerosis involves a slow process of plaque formation on the walls of arteries, and comprises a leading cause of cardiovascular disease. Long non-coding RNAs (lncRNAs) have been implicated in the pathogenesis of atherosclerosis. In this study, we aim to explore the possible involvement of lncRNA 'cyclin-dependent kinase inhibitor 2B antisense noncoding RNA' (CDKN2B-AS1) and CDKN2B in the progression of atherosclerosis.
Methods: Initially, we quantified the expression of CDKN2B-AS1 in atherosclerotic plaque tissues and, in THP-1 macrophage-derived, and human primary macrophage (HPM)-derived foam cells. Next, we established a mouse model of atherosclerosis using apolipoprotein E knockout (ApoE) mice, where lipid uptake, lipid accumulation, and macrophage reverse cholesterol transport (mRCT) were assessed, in order to explore the contributory role of CDKN2B-AS1 to the progression of atherosclerosis. RIP and ChIP assays were used to identify interactions between CDKN2B-AS1, CCCTC-binding factor (CTCF), enhancer of zeste homologue 2 (EZH2), and CDKN2B. Triplex formation was determined by RNA-DNA pull-down and capture assay as well as EMSA experiment.
Findings: CDKN2B-AS1 showed high expression levels in atherosclerosis, whereas CDKN2B showed low expression levels. CDKN2B-AS1 accelerated lipid uptake and intracellular lipid accumulation whilst attenuating mRCT in THP-1 macrophage-derived foam cells, HPM-derived foam cells, and in the mouse model. EZH2 and CTCF were found to bind to the CDKN2B promoter region. An RNA-DNA triplex formed by CDKN2B-AS1 and CDKN2B promoter was found to recruit EZH2 and CTCF in the CDKN2B promoter region and consequently inhibit CDKN2B transcription by accelerating histone methylation.
Interpretation: The results demonstrated that CDKN2B-AS1 promotes atherosclerotic plaque formation and inhibits mRCT in atherosclerosis by regulating CDKN2B promoter, and thereby could be a potential therapeutic target for atherosclerosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184162 | PMC |
| http://dx.doi.org/10.1016/j.ebiom.2020.102694 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Molecular basis of symptomatic sporadic primary hyperparathyroidism: New frontiers in pathogenesis.
Best Pract Res Clin Endocrinol Metab
March 2025
Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India. Electronic address:
Primary hyperparathyroidism is a common endocrine disorder characterized by inappropriate elevation of parathyroid hormone and hypercalcemia. While predominantly an asymptomatic disease in Western populations, symptomatic presentations are more prevalent in Eastern countries. The molecular pathogenesis of sporadic PHPT primarily involves genetic and epigenetic alterations leading to abnormal parathyroid cell proliferation and altered calcium sensing mechanism.
View Article and Find Full Text PDFGenomic Analysis of Advanced Phyllodes Tumors Using Next-Generation Sequencing and Their Chemotherapy Response: A Retrospective Study Using the C-CAT Database.
Medicina (Kaunas)
November 2024
Department of Gastroenterology, Yamagata City Hospital Saiseikan, 1-2-26 Nanokamachi, Yamagata 990-0042, Japan.
Article Synopsis
- Phyllodes tumors are rare breast tumors with limited treatment options, and this study aimed to explore their genomic changes and associate them with treatment outcomes using Japan's C-CAT clinical genomic registry.
- A retrospective analysis of 60 cases revealed common genetic mutations, like TERT promoter variants and TP53 mutations, and showed that some alterations might predict treatment resistance, although the results weren't statistically significant.
- The study highlights unique molecular characteristics of phyllodes tumors, suggesting these genetic insights could inform personalized treatment strategies and identify potential targets for therapy.
Frequency and Prognostic Impact of CDKN2A/B Alteration in Oligodendrogliomas: Systematic Review and Meta-analysis.
Neurol Med Chir (Tokyo)
December 2024
Department of Neurosurgery, Shiga University of Medical Science.
Isocitrate dehydrogenase (IDH) -mutant astrocytomas with homozygous deletion of cyclin-dependent kinase 2A/B (CDKN2A/B-HomoD) are categorized to grade 4 in the new World Health Organization (WHO) classification. However, the clinical implications of CDKN2A/B-HomoD in oligodendrogliomas remain unclear. This study systematically reviewed and meta-analyzed the literature on molecularly defined oligodendrogliomas (mOlig) to find the frequency and prognostic significance of CDKN2A/B gene alterations.
View Article and Find Full Text PDFGenomic landscape of malignant phyllodes tumors reveals multiple targetable opportunities.
Oncologist
December 2024
Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, United States.
Article Synopsis
- Malignant phyllodes tumors (MPT) are rare breast cancers with a poor prognosis, prompting researchers to analyze their genomic characteristics and potential immunotherapy markers.
- The study involved genomic profiling of 135 MPT cases, revealing that 69.6% were localized, with a median age of 54 and several patients demonstrating actionable mutations.
- Findings indicate that routine genomic sequencing for metastatic MPT may improve treatment strategies and help in enrolling patients in clinical trials.
Divergent DNA methylation patterns and gene expression in MYC and in canine transmissible venereal tumors.
Vet World
July 2024
Veterinary Bioscience Unit, Veterinary Academic Office, Faculty of Veterinary Medicine, Chiang Mai University, Chiang Mai, 50100 Thailand.
Background And Aim: Canine transmissible venereal tumor (CTVT), a unique transmissible cancer in dogs, affects the external genitalia and potentially spreads to other parts of the body. While somatic mutations in oncogenic and tumor-suppressing genes are linked to CTVT development, the impact of DNA methylation, which affects gene expression, remains unclear. This study explored whether DNA methylation in the promoter regions of the MYC oncogene and tumor suppressor genes in CTVTs is associated with their expression, both at the gene and protein levels.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!